Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AZ's Oral PCSK9 Inhibitor halves Bad Cholesterol in Phase 2
Details : AZD0780 is an oral, small molecule PCSK9 inhibitor that is being developed by AstraZeneca as an innovative therapy for patients with elevated low-density lipoprotein cholesterol (LDL-C) levels.
Product Name : AZD0780
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 31, 2025
Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : YS2302018,Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : AstraZeneca
Deal Size : $2,020.0 million
Deal Type : Licensing Agreement
AstraZeneca Puts $2B on The Line for Preclinical Heart Disease Drug
Details : AstraZeneca will receive access to CSPC’s pre-clinical candidate small molecule, YS2302018, an oral Lp(a) disruptor, with the aim of developing in a range of cardiovascular disease.
Product Name : YS2302018
Product Type : Other Small Molecule
Upfront Cash : $100.0 million
July 10, 2024
Lead Product(s) : YS2302018,Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : AstraZeneca
Deal Size : $2,020.0 million
Deal Type : Licensing Agreement
Reset All
